PLXEarnings•prnewswire•
Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results
Sentiment:Negative (20)
Summary
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, Aug. 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 14, 2025 by prnewswire